Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. - Wikidata - wikimedia - TriplyDB

Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.

Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.

http://www.wikidata.org/entity/Q37345807

about

Therapy-related myeloid neoplasms - what have we learned so far?Therapy-related myeloid neoplasms: pathobiology and clinical characteristics Evaluation of BM cytomorphology after allo-SCT in patients with AML.Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.Hematopoietic stem cell transplantation for MDS.Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy Isolated clonal cytogenetic abnormalities after high-dose therapy.Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retros Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplasti Prognosis and therapy when acute promyelocytic leukemia and other "good risk" acute myeloid leukemias occur as a therapy-related myeloid neoplasm.Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine Current status of allogeneic hematopoietic cell transplantation for MDS.Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome.Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome.Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade.Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.Therapy-related myeloid leukemia.Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis.Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation Therapy-related myelodysplasia and acute myeloid leukemia Interactive diagnostics in the indication to allogeneic SCT in AML.Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation.Acute leukemia in women.Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.Concise review: the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia.Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective.Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process.Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients.Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma.

P2860

Q28071318-DE54EB80-9B8C-4BEF-B01A-EEFBA4945710 Q28386366-CA88E986-80E6-406D-91C4-1F6938998896 Q30318110-A96E2FE4-D049-446E-8BB9-8D80AC5FB3BE Q33706393-CE7A691A-199F-4E72-AAFB-E75FF33B9116 Q33718837-30F49D8B-875B-436D-8EB8-BF76D4DF21F4 Q33767314-4299210A-9CF0-4113-A6FF-48556D793C2B Q33847018-B6B261C6-4A37-4B44-8690-A381670EA38B Q33928011-A1FF9CBD-7C86-4A6B-8295-2951C5AB58DA Q34108964-F8453D23-9637-4DB5-BE88-A7F8D1EB8E48 Q34272525-B6A700AB-8FF0-42A3-B6EB-2ABA190E3C9A Q34684038-D348A362-EC51-4A83-A07C-F31D2C44F845 Q35146316-C2B519C5-0B7D-4D5D-8068-13AD85D08BF6 Q35153662-AFCFB6FA-FABA-4CE5-9523-34522B0C8896 Q35574597-A88EBD6B-6D97-4106-B993-5ECF07753237 Q36029093-12492C03-9ED2-451A-AC01-733B18737F23 Q36063049-3D54F076-586E-4160-819F-3FDA0533F0C0 Q36339459-02C4C6DD-5530-4513-8C1F-47A6E5B8899A Q36402045-302EB85B-2DE6-46D0-AD92-D989067F65AD Q36579060-0939B30A-2C2D-421D-9944-314B2B72C4B2 Q36579081-A556F07B-4A11-4A32-BA47-2C8A9417D06E Q36683757-2B3553B9-14F2-4605-B568-4A47FDB7FE59 Q36713551-6C798186-3876-49FB-9E2D-D76E1739196C Q36811828-48A3A828-9C3F-417B-8681-472CDF3B74F7 Q36961604-0EF96081-8663-436C-9148-8DF84D2D2A32 Q37009760-3A9FFCA6-E087-4EDA-AAC2-5458486357C3 Q37146052-97718F7C-765D-41F4-978F-0EA9A4896C62 Q37163850-9F7EA60F-EDD8-4B63-A0C8-6DA2AF113529 Q37296965-3AE50B1B-FB63-4802-9E00-FDC17E91C977 Q37354189-F77DA399-0A1E-4695-A16C-6981F22F5362 Q37402657-4DE6CB11-7E91-4A6D-81BD-E550B9971D74 Q37442649-D67F4240-9199-48FB-8334-85B2FE4B8E52 Q37486793-D810D402-9251-4BF1-B1C0-9DA68D356EEE Q37699362-F64F13E6-A8C1-4135-8C2E-4BC16D32ABAD Q37964938-B1D18B4A-34E2-4222-A770-5EBFBD6DDC46 Q38015268-D140B945-5F46-43D7-B7C6-48662D4FB903 Q38248427-4910BF4C-AEF1-4C2B-975A-B4EF4BF72F0F Q38542828-28304B2D-8786-456D-8230-DE832DD8E060 Q38657161-D88D267E-264C-41FF-A45A-DA56C9BC8A41 Q38852431-F15E9DB4-1D16-4F81-98BF-62140A08AACA Q38881049-BC027AEA-8CFF-48D2-967B-19DF96CC048F

P2860

Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.

http://www.wikidata.org/entity/Q37345807

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 March 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Impact of cytogenetics on outc ...... er allogeneic transplantation.

@en

Impact of cytogenetics on outc ...... er allogeneic transplantation.

@nl

type

label

Impact of cytogenetics on outc ...... er allogeneic transplantation.

@en

Impact of cytogenetics on outc ...... er allogeneic transplantation.

@nl

prefLabel

Impact of cytogenetics on outc ...... er allogeneic transplantation.

@en

Impact of cytogenetics on outc ...... er allogeneic transplantation.

@nl

P1433

Q37345807-D04EA43E-0E7C-4F33-84F4-C1B863048F94

P1476

Q37345807-132DD9E8-ADB6-4A5A-A145-6E2F66B5D973

P2093

Q37345807-1AC1D80D-6CC9-46BB-960C-843F6DD9E854

Q37345807-2F16074D-ADA9-4B81-80EA-45417DB63977

Q37345807-559A5F93-1099-4548-A9F2-0D79FB1E7748

Q37345807-91D6879B-4860-4989-A8E5-5FA369699E42

Q37345807-C6C7A8BE-A950-43D9-B559-0F8737E4968B

Q37345807-CDDF5BCE-DF5D-45BB-8D3A-3F1C2FB292D4

Q37345807-D91EC60C-592C-4486-B431-31B31086C668

Q37345807-ED49ABBC-0C0E-465E-B884-F84967D89F4C

Q37345807-F0A98F90-B245-42D5-833E-B29643E007BB

Q37345807-FAC5D2FD-B727-4ABC-A0E6-CDC46120BB33

P2860

Q37345807-05E1AD57-9ECE-4E6B-9305-F115EB82E5C7

Q37345807-06C2550E-384F-4C68-90FD-9A4214566E4D

Q37345807-105A3072-39EC-4403-9B49-CBF397645283

Q37345807-132CDF53-C09A-4863-801F-77579E9F5709

Q37345807-15737F82-CECC-4F1C-B744-4884A95350E0

Q37345807-1DE89437-DF96-4F59-8497-6767D7AD49AA

Q37345807-23C20691-5491-43CB-9429-B86AC9D48588

Q37345807-30E9DB32-150D-4D5B-AC13-C131752ECA93

Q37345807-4E31F5AF-B6BB-4AAF-9106-B515C1124B6E

Q37345807-55039ACD-353F-4727-8BBC-253130726C63

P304

Q37345807-B7523679-405C-473F-9FF5-9482FF6C19CA

P31

Q37345807-7DE8824C-D97A-4920-98B9-E2B2233653E7

P356

Q37345807-254616C0-853D-44F7-951C-01FBC80695C2

P433

Q37345807-C09E8AC3-7254-4D1F-932C-D1A40D4068B0

P478

Q37345807-218D0319-BD28-4A54-BD86-A007406A0815

P577

Q37345807-6C170905-DBF8-413A-A2A7-A81082A87DDC

P5875

Q37345807-4F1AAD11-EC7E-4A06-B03D-EF1D558DE27F

P698

Q37345807-A12AE800-2C0D-4DFA-A751-60C9EB1FB508

P932

Q37345807-BCEA6967-2E20-4DDD-8D81-D4BCF60EF833

P356

J.BBMT.2007.01.079

P1433

Biology of Blood and Marrow Transplantation

P1476

Impact of cytogenetics on outc ...... er allogeneic transplantation.

@en

P2093

Corey S Cutler

http://www.w3.org/2001/XMLSchema#string

Daniel J DeAngelo

http://www.w3.org/2001/XMLSchema#string

Edwin P Alyea

http://www.w3.org/2001/XMLSchema#string

Haesook T Kim

http://www.w3.org/2001/XMLSchema#string

Jerome Ritz

http://www.w3.org/2001/XMLSchema#string

Joseph H Antin

http://www.w3.org/2001/XMLSchema#string

Philippe Armand

http://www.w3.org/2001/XMLSchema#string

Richard M Stone

http://www.w3.org/2001/XMLSchema#string

Robert J Soiffer

http://www.w3.org/2001/XMLSchema#string

Vincent T Ho

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

International scoring system for evaluating prognosis in myelodysplastic syndromes

Impact of cytogenetics on outcome of stem cell transplantation for acute myeloid leukemia in first remission: a large-scale retrospective analysis of data from the Japan Society for Hematopoietic Cell Transplantation.

Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia.

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.

Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

P304

655-664

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2007.01.079

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6303550

http://www.w3.org/2001/XMLSchema#string

P698

17531775

http://www.w3.org/2001/XMLSchema#string

P932

2743535

http://www.w3.org/2001/XMLSchema#string